Expansion expected to create additional production capacity, company says.
Starting this year, Novo Nordisk announced plans to invest over $2 billion to increase its Active Pharmaceutical Ingredient (API) production facility in Denmark. Expected to increase production capacity, the announcement comes as the organization has struggled to meet demand for injectable medications such as Wegovy.
Expected to be ready for API production in 2029, the project will reportedly create over 340 jobs once completed.
“This important investment will ensure the continuous development of our late-phase pipeline into deliveries of important medicines for treatments to patients worldwide,” said Henrik Wulff, EVP, product supply, quality & IT, Novo Nordisk. “The investment announced today confirms Hillerød and Denmark as cornerstones in our global footprint, and I would like to take this opportunity to thank the Danish government and parliament for their continued focus on ensuring good and stable infrastructure and supplies – allowing us to continue to expand our production capacity to the benefit of patients living with serious chronic diseases.”
Reference: Novo Nordisk invests DKK 15.9 bn in expansion of manufacturing facilities in Hillerød, Denmark. GlobeNewswire. June 12, 2023. Accessed June 14, 2023. https://www.globenewswire.com/news-release/2023/06/12/2685963/0/en/Novo-Nordisk-invests-DKK-15-9-bn-in-expansion-of-manufacturing-facilities-in-Hiller%C3%B8d-Denmark.html